Compare Charles River Laboratories Intl. Inc (CRL) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $226.78 (market cap $11.14B), while Rex Fang & Innovation Equity Premium Income ETF trades at $42.14. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| CRL | FEPI | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $233.60 | $49.54 |
52-Week Low | $145.57 | $38.13 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $41.98, down 1.65% with a bearish technical signal. The ETF employs an aggressive covered call strategy on concentrated AI and mega-cap tech holdings, generating weekly dividends averaging $0.21-0.22 recently. Technical indicators show bearish momentum with resistance at $43 and support at $42, while oscillators remain neutral. The fund's 25% yield attracts retail investors but comes with NAV erosion concerns during market downturns.
FEPI offers high income potential but faces structural limitations from its covered call strategy that caps upside during tech rallies. The concentrated portfolio of high-beta names amplifies downside risk, making it suitable for income-focused investors willing to accept limited capital appreciation. Recent transition to weekly distributions enhances compounding but doesn't address fundamental NAV erosion risks in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
